AQP4 and autoimmune disease: 9. We recommend that the choice among eculizumab, inebilizumab, ravulizumab, or satralizumab consider factors such as drug availability, comorbidities, other autoimmune disorders, and patient preference, since efficacy and safety have not been compared in head-to-head studies in AQP4-IgG-seropositive pwNMOSD.